Neurology News

Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia.

Marriage was associated with a lower risk for dementia and mild cognitive impairment in later life, researchers reported in the Journal of Aging and Health.

Aculys Pharma, Inc. announced the initiation of a phase 3 trial of pitolisant, a histamine H3 receptor antagonist/inverse agonist in those with excessive daytime sleepiness that is associated with obstructive sleep apnea syndrome.

The FDA has approved the Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy, manufacturer Abbott announced in a press release.

Reduced kidney function was associated with increased levels of dementia-related blood biomarkers, but not an increased risk for Alzheimer’s disease or dementia, researchers reported in JAMA Network Open.

A web-based system for the diagnosis and treatment of recurrent benign paroxysmal positional vertigo was shown to be effective, researchers reported in JAMA Neurology.

PB006, the first biosimilar for natalizumab, showed comparable safety, efficacy and immunogenicity to the reference monoclonal antibody therapy in patients with relapsing-remitting MS, researchers wrote in JAMA Neurology.

Head injury was associated with decreased long-term survival time in a community-based cohort with more than 30 years of follow-up, researchers wrote in JAMA Neurology.

Neurogene Inc. announced the FDA has granted clearance to its investigational new drug application for NGN-401, an adeno-associated virus gene therapy candidate for treating Rett syndrome in female pediatric patients.

Sleep quality in patients with type 1 diabetes may be improved with disease management as well as interventions supporting resilience and reducing negative emotions, researchers reported in BMC Psychiatry.